Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.

The management of CNS tumors is limited by the blood-brain barrier (BBB), a vascular interface that restricts the passage of most molecules from the blood into the brain. Here we show that phage particles targeted with certain ligand motifs selected in vivo from a combinatorial peptide library can cross the BBB under normal and pathological conditions. Specifically, we demonstrated that phage clones displaying an iron-mimic peptide were able to target a protein complex of transferrin and transferrin receptor (TfR) through a non-canonical allosteric binding mechanism and that this functional protein complex mediated transport of the corresponding viral particles into the normal mouse brain. We also showed that, in an orthotopic mouse model of human glioblastoma, a combination of TfR overexpression plus extended vascular permeability and ligand retention resulted in remarkable brain tumor targeting of chimeric adeno-associated virus/phage particles displaying the iron-mimic peptide and carrying a gene of interest. As a proof of concept, we delivered the HSV thymidine kinase gene for molecular-genetic imaging and targeted therapy of intracranial xenografted tumors. Finally, we established that these experimental findings might be clinically relevant by determining through human tissue microarrays that many primary astrocytic tumors strongly express TfR. Together, our combinatorial selection system and results may provide a translational avenue for the targeted detection and treatment of brain tumors.

[1]  D. Choudhury,et al.  Tertiary structural changes associated with iron binding and release in hen serum transferrin: a crystallographic and spectroscopic study. , 2004, Biochemical and biophysical research communications.

[2]  R. MacGillivray,et al.  Inequivalent contribution of the five tryptophan residues in the C-lobe of human serum transferrin to the fluorescence increase when iron is released. , 2009, Biochemistry.

[3]  I. Trowbridge,et al.  Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells , 1981, Nature.

[4]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[5]  W. Pardridge,et al.  Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.

[6]  W. Banks Are the Extracellular Pathways a Conduit for the Delivery of Therapeutics to the Brain , 2004 .

[7]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[8]  H. Davson Blood–brain barrier , 1977, Nature.

[9]  A. Mason,et al.  Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor , 2009, JBIC Journal of Biological Inorganic Chemistry.

[10]  W. Pardridge Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. , 2008, Bioconjugate chemistry.

[11]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[12]  W. Arap,et al.  Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU , 2007, Nature Protocols.

[13]  Kim-Anh Do,et al.  Steps toward mapping the human vasculature by phage display , 2002, Nature Medicine.

[14]  Thomas Walz,et al.  Structure of the Human Transferrin Receptor-Transferrin Complex , 2004, Cell.

[15]  I. Verma,et al.  Targeted delivery of proteins across the blood–brain barrier , 2007, Proceedings of the National Academy of Sciences.

[16]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[17]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[18]  W. Pardridge Drug Targeting to the Brain , 2007, Pharmaceutical Research.

[19]  Emmanuel Dias-Neto,et al.  Next-Generation Phage Display: Integrating and Comparing Available Molecular Tools to Enable Cost-Effective High-Throughput Analysis , 2009, PloS one.

[20]  B. Zlokovic The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[21]  W. Pardridge,et al.  A One‐Step Procedure for Isolation of Poly(A)+ mRNA from Isolated Brain Capillaries and Endothelial Cells in Culture , 1991, Journal of neurochemistry.

[22]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[23]  W. Pardridge,et al.  Marked enhancement in gene expression by targeting the human insulin receptor , 2003, The journal of gene medicine.

[24]  W. Banks,et al.  Isolation of Peptide Transport System-6 from Brain Endothelial Cells: Therapeutic Effects with Antisense Inhibition in Alzheimer and Stroke Models , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  R. MacGillivray,et al.  Ligand-induced conformational change in transferrins: crystal structure of the open form of the N-terminal half-molecule of human transferrin. , 1998, Biochemistry.

[26]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[27]  W. Pardridge,et al.  Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[28]  W. Arap,et al.  Design and construction of targeted AAVP vectors for mammalian cell transduction , 2007, Nature Protocols.

[29]  Kim-Anh Do,et al.  Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. , 2006, Cancer research.

[30]  J. Nutt,et al.  Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.

[31]  G. Baldwin Comparison of transferrin sequences from different species. , 1993, Comparative biochemistry and physiology. B, Comparative biochemistry.

[32]  H. Baker,et al.  Two high-resolution crystal structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron release. , 1998, Biochemistry.

[33]  R Weissleder,et al.  Measuring transferrin receptor gene expression by NMR imaging. , 1998, Biochimica et biophysica acta.

[34]  H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[35]  C. Lilley,et al.  A Hybrid Vector for Ligand-Directed Tumor Targeting and Molecular Imaging , 2006, Cell.

[36]  R. Sidman,et al.  Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems. , 2008, Trends in cardiovascular medicine.

[37]  W. Banks Delivery of peptides to the brain: emphasis on therapeutic development. , 2008, Biopolymers.

[38]  J. Humm,et al.  Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. , 1998, Cancer research.

[39]  W. Arap,et al.  A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging , 2008, Proceedings of the National Academy of Sciences.

[40]  R. MacGillivray,et al.  Intrinsic fluorescence reports a global conformational change in the N-lobe of human serum transferrin following iron release. , 2007, Biochemistry.

[41]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[42]  Wadih Arap,et al.  Biopanning and rapid analysis of selective interactive ligands , 2001, Nature Medicine.

[43]  Z. M. Shen,et al.  Conformational stability of porcine serum transferrin , 1992, Protein science : a publication of the Protein Society.

[44]  R. Starzyk,et al.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Fuller,et al.  An implantable guide-screw system for brain tumor studies in small animals. , 2000, Journal of neurosurgery.

[46]  G. Reifenberger,et al.  Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction , 2005, Virchows Archiv A.

[47]  C. Merril,et al.  Fate of Bacteriophage Lambda in Non-immune Germ-free Mice , 1973, Nature.

[48]  L. Recht,et al.  Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. , 1990, Journal of neurosurgery.

[49]  O. L. Davies,et al.  Studies on the blood-brain barrier; the basis of dosage for animals of various weights. , 1948, British journal of pharmacology and chemotherapy.

[50]  W. Pardridge,et al.  Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouse , 2009, Biotechnology and bioengineering.

[51]  R. Broadwell,et al.  Endocytic and exocytic pathways of the neuronal secretory process and trans synaptic transfer of wheat germ agglutinin‐horseradish peroxidase in vivo , 1985, The Journal of comparative neurology.

[52]  G. Fuller,et al.  Overexpression of IGFBP5, but not IGFBP3, Correlates with the Histologic Grade of Human Diffuse Glioma: A Tissue Microarray and Immunohistochemical Study , 2006, Technology in cancer research & treatment.

[53]  W. Pardridge,et al.  Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.